✨ Free AI Report
Solid Biosciences Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Solid Biosciences Inc.
Company Research

Solid Biosciences Inc.: Business Overview, Financials & Competitive Analysis

Solid Biosciences Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage gene therapy platform with promising clinical progression in rare genetic diseases facing typical biotech execution and capital challenges. While SLDB has a great health rating, there are worries on its profitability. February brought positive FDA Type C feedback for SGT-003's Phase 3 IMPACT DUCHENNE trial, with 36 Phase.

What is Solid Biosciences Inc.'s industry? Solid Biosciences Inc. (solidbio.com) operates in Biotechnology / Precision Gene Therapy. AskCyborg classifies Solid Biosciences Inc. under Biotechnology / Precision Gene Therapy in its company registry.

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreic...

5/ 10Mixed

Cyborg Score thesis

Early-stage gene therapy platform with promising clinical progression in rare genetic diseases facing typical biotech execution...

Read the full analyst-debate transcript →
Industry Biotechnology / Precision Gene Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Solid Biosciences Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Solid Biosciences Inc.

AskCyborg analysts argue the bull and bear cases for Solid Biosciences Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Solid Biosciences Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Solid Biosciences Inc. Overview

Pro stress-test →

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, catecholaminergic polymorphic ventricular tachycardia, TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.

Strategic Profile

Pro stress-test →

The company is involved in developing platform technologies, including capsid libraries, genetic regulators such as promoters, UTRs, and introns, immunomodulation technologies, manufacturing purity, and dual gene expression, a technology for packaging multiple transgenes into one capsid. Founded by those directly impacted by Duchenne, Solid's mission is to improve the daily lives of patients living with devastating rare diseases.

Competitive Landscape

Pro stress-test →

Solid Biosciences competes in the rare genetic disease gene therapy space with companies like Sarepta Therapeutics, REGENXBIO, and Wave Life Sciences. The company differentiates through its proprietary platform technologies and diverse pipeline spanning both neuromuscular and cardiac indications, allowing for potential synergies and cross-program learnings.

Industry Context

Solid Biosciences Inc. operates in Biotechnology / Precision Gene Therapy.

Key facts

Founded: 2018 · Headquarters: Charlestown, Massachusetts, United States · Employees: 100 · Revenue: N/A · Market cap: $490M - $510M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Solid Biosciences Inc..

  • Lead program SGT-003 for Duchenne muscular dystrophy advancing in Phase 1/2 with recent FDA positive feedback for Phase 3 trial
  • Diversified pipeline across rare neuromuscular and cardiac indications reducing single-program risk
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026FDA Orphan Drug designation and first dosing in FALCON trial for SGT-212
  • February 2026Positive FDA Type C feedback for SGT-003 Phase 3 IMPACT DUCHENNE trial
  • +1 moreTrack every material event for Solid Biosciences Inc. as it happens. Explore monitoring →
Get alerted when Solid Biosciences Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gene therapy for Duchenne muscular dystrophyEstablished gene therapy player in neuromuscular diseases→AAV-based gene therapy platformGene therapy platform provider focusing on rare genetic diseases→Gene therapy programsGenetic medicine company with rare disease focus→

Compare Solid Biosciences Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Solid Biosciences Inc. operates in Biotechnology / Precision Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Precision Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Solid Biosciences Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Solid Biosciences Inc. and its top competitor on Cyborg Score”
“What did Solid Biosciences Inc. do this quarter?”
“Is Solid Biosciences Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Solid Biosciences Inc. do?+
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreic...
What is Solid Biosciences Inc.'s Cyborg Score?+
Solid Biosciences Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Solid Biosciences Inc.'s main competitors?+
Named competitors include Gene therapy for Duchenne muscular dystrophy, AAV-based gene therapy platform, Gene therapy programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Solid Biosciences Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Solid Biosciences Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Solid Biosciences Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score